Literature DB >> 17199821

The balm of Gilead: is the provision of treatment to those who seroconvert in HIV prevention trials a matter of moral obligation or moral negotiation?

Charles Weijer1, Guy J Leblanc.   

Abstract

Must treatment be provided to subjects who acquire HIV during the course of a prevention study? An analysis of ethical foundation, regulation, and recent argumentation provides no basis for the obligation. We outline an alternative approach to the problem based on moral negotiation.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17199821     DOI： 10.1111/j.1748-720X.2006.00099.x

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN： 1073-1105            Impact factor:   1.718


  9 in total

1.  Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach.

Authors:  Stuart Rennie; Jeremy Sugarman
Journal:  J Med Ethics       Date:  2010-12       Impact factor: 2.903

Review 2.  Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective.

Authors:  Pamela Andanda; Jane Wathuta
Journal:  Med Health Care Philos       Date:  2018-03

3.  Post-trial access to antiretrovirals: who owes what to whom?

Authors:  Joseph Millum
Journal:  Bioethics       Date:  2011-03       Impact factor: 1.898

4.  Legal and ethical values in the resolution of research-related disputes: how can IRBS respond to participant complaints?

Authors:  Kristen Underhill
Journal:  J Empir Res Hum Res Ethics       Date:  2014-02       Impact factor: 1.742

5.  Ancillary care in South African HIV vaccine trials: addressing needs, drafting protocols, and engaging community.

Authors:  Catherine M Slack
Journal:  J Empir Res Hum Res Ethics       Date:  2014-02       Impact factor: 1.742

6.  Partnering for Care in HIV Prevention Trials.

Authors:  Kathleen M Macqueen; Kerry McLoughlin; Patty Alleman; Holly McClain Burke; Natasha Mack
Journal:  J Empir Res Hum Res Ethics       Date:  2008-12       Impact factor: 1.742

7.  Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents.

Authors:  Andrea L Ciaranello; Rochelle P Walensky; Paul E Sax; Yuchiao Chang; Kenneth A Freedberg; Joel S Weissman
Journal:  HIV Clin Trials       Date:  2009 Jan-Feb

8.  Stakeholder views of ethical guidance regarding prevention and care in HIV vaccine trials.

Authors:  Rika Moorhouse; Catherine Slack; Michael Quayle; Zaynab Essack; Graham Lindegger
Journal:  BMC Med Ethics       Date:  2014-06-30       Impact factor: 2.652

9.  Improving ethical and participatory practice for marginalized populations in biomedical HIV prevention trials: lessons from Thailand.

Authors:  Dan Allman; Melissa Hope Ditmore; Karyn Kaplan
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.